You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
Baxter
Medtronic
Johnson and Johnson

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

VISTIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Vistide, and what generic alternatives are available?

Vistide is a drug marketed by Gilead Sciences Inc and is included in one NDA.

The generic ingredient in VISTIDE is cidofovir. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cidofovir profile page.

US ANDA Litigation and Generic Entry Outlook for Vistide

A generic version of VISTIDE was approved as cidofovir by MYLAN INSTITUTIONAL on June 27th, 2012.

  Start Trial

Summary for VISTIDE
Drug patent expirations by year for VISTIDE
Recent Clinical Trials for VISTIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PennsylvaniaPhase 2
National Cancer Institute, FrancePhase 1
Gustave Roussy, Cancer Campus, Grand ParisPhase 1

See all VISTIDE clinical trials

US Patents and Regulatory Information for VISTIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc VISTIDE cidofovir INJECTABLE;INJECTION 020638-001 Jun 26, 1996 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VISTIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0253412 97C0105 Belgium   Start Trial PRODUCT NAME: CIDOFOVIR; REGISTRATION NO/DATE: EU/1/97/037/001 19970423
0253412 63/1997 Austria   Start Trial PRODUCT NAME: CIDOFOVIR; REGISTRATION NO/DATE: K (97) 1176 19970423
0253412 SPC/GB97/083 United Kingdom   Start Trial PRODUCT NAME: CIDOFOVIR; REGISTERED: UK EU/1/97/037/001 19970423
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Merck
McKinsey
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.